dupilumab
regeneron,sanofi
['dupilumab', 'derm']
patients with pn who had severe itch and high lesion counts and whose condition was inadequately controlled with prior therapies, experienced significant improvements with dupilumab, indicate results from liberty-pn prime trial. #eadvcongress #dermtwitter 
MDedge Dermatology provides the most important and up to date information and news for dermatologists. Now part of the Medscape Professional Network.